Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 2

Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients

Authors Zheng-Xiong Xi

Published Date April 2010 Volume 2010:2 Pages 39—48

DOI http://dx.doi.org/10.2147/DHPS.S6299

Published 14 April 2010

Zheng-Xiong Xi

National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA

Abstract: Smoking is still the most prominent cause of preventable premature death in the United States and an increasing cause of morbidity and mortality throughout the world. Although the current treatments such as nicotine replacement therapy (NRT) and bupropion are effective, long-term abstinence rates are low. Mechanism studies suggest that the pleasurable effects of smoking are mediated predominantly by nicotine, which activates the brain reward system by activation of brain α4β2 nicotinic acetylcholine receptors (nAChRs). Varenicline is a novel α4β2 nAChR partial agonist and has been found to be even more effective than NRT or bupropion in attenuating smoking satisfaction and in relieving craving and withdrawal symptoms after abstinence. Thus, varenicline has been recently approved to be a first-line medication for smoking cessation in the United States and European countries. Varenicline is generally well tolerated in healthy adult smokers, with the most commonly reported adverse effects being nausea, insomnia, and headache. However, growing postmarketing data has linked varenicline to an increase in neuropsychiatric symptoms such as seizures, suicidal attempts, depression, and psychosis as well as serious injuries potentially relating to unconsciousness, dizziness, visual disturbances, or movement disorders. Therefore, new safety warnings are issued to certain high risk populations, such as patients with mental illness and operators of commercial vehicles and heavy machinery. In particular, pilots, air traffic controllers, truck and bus drivers have been banned from taking varenicline.

Keywords: nicotine, varenicline, α4β2 nicotinic acetylcholine receptor, nAChRs, partial agonist, smoking cessation

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Respiratory training as strategy to prevent cognitive decline in aging: a randomized controlled trial

Ferreira L, Tanaka K, Santos-Galduróz RF, Galduróz JCF

Clinical Interventions in Aging 2015, 10:593-603

Published Date: 20 March 2015

Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial

Checa MA, Brassesco M, Sastre M, Gómez M, Herrero J, Marque L, Brassesco A, Espinós JJ

International Journal of Women's Health 2015, 7:219-225

Published Date: 12 February 2015

Patient inclusion in transfusion medicine: current perspectives

Friedman MT, Bizargity P, Gilmore S, Friedman A

International Journal of Clinical Transfusion Medicine 2015, 3:7-16

Published Date: 13 January 2015

Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids

Galbis-Estrada C, Pinazo-Durán MD, Cantú-Dibildox J, Marco-Ramírez C, Díaz-Llópis M, Benítez-del-Castillo J

Clinical Interventions in Aging 2013, 8:711-719

Published Date: 19 June 2013

DataGenno: building a new tool to bridge molecular and clinical genetics

Fabricio F Costa, Luciano S Foly, Marcelo P Coutinho

The Application of Clinical Genetics 2011, 4:45-54

Published Date: 18 March 2011